KR20230107566A - 세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물 - Google Patents

세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물 Download PDF

Info

Publication number
KR20230107566A
KR20230107566A KR1020237015543A KR20237015543A KR20230107566A KR 20230107566 A KR20230107566 A KR 20230107566A KR 1020237015543 A KR1020237015543 A KR 1020237015543A KR 20237015543 A KR20237015543 A KR 20237015543A KR 20230107566 A KR20230107566 A KR 20230107566A
Authority
KR
South Korea
Prior art keywords
methyl
dimethylamino
ethoxy
phenyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015543A
Other languages
English (en)
Korean (ko)
Inventor
라리아 줄리오 카스트로-팔로미노
고메즈 후안 알베르토 카마초
리수에뇨 루스 무뇨스
리즈 클레멘트-디망지
Original Assignee
레우코스 바이오테크 에스. 엘.
푼다시오 인스티뚜트 데 레세르카 꼰뜨라 라 레우세미아 요셉 까를레라스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레우코스 바이오테크 에스. 엘., 푼다시오 인스티뚜트 데 레세르카 꼰뜨라 라 레우세미아 요셉 까를레라스 filed Critical 레우코스 바이오테크 에스. 엘.
Publication of KR20230107566A publication Critical patent/KR20230107566A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237015543A 2020-10-08 2021-10-07 세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물 Pending KR20230107566A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382888.4 2020-10-08
EP20382888 2020-10-08
PCT/EP2021/077660 WO2022074103A1 (en) 2020-10-08 2021-10-07 Potent and selctive compounds as serotonin 1b receptor modulators

Publications (1)

Publication Number Publication Date
KR20230107566A true KR20230107566A (ko) 2023-07-17

Family

ID=73030029

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015543A Pending KR20230107566A (ko) 2020-10-08 2021-10-07 세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물

Country Status (21)

Country Link
US (2) US12540133B2 (cg-RX-API-DMAC10.html)
EP (2) EP4225753B1 (cg-RX-API-DMAC10.html)
JP (1) JP7687636B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230107566A (cg-RX-API-DMAC10.html)
CN (1) CN116635390B (cg-RX-API-DMAC10.html)
AU (1) AU2021356114A1 (cg-RX-API-DMAC10.html)
CA (1) CA3194700A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001021A1 (cg-RX-API-DMAC10.html)
DK (1) DK4225753T3 (cg-RX-API-DMAC10.html)
ES (1) ES2985416T3 (cg-RX-API-DMAC10.html)
FI (1) FI4225753T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241184T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068199T2 (cg-RX-API-DMAC10.html)
IL (1) IL301806B2 (cg-RX-API-DMAC10.html)
LT (1) LT4225753T (cg-RX-API-DMAC10.html)
MX (1) MX2023004116A (cg-RX-API-DMAC10.html)
PL (1) PL4225753T3 (cg-RX-API-DMAC10.html)
PT (1) PT4225753T (cg-RX-API-DMAC10.html)
RS (1) RS65956B1 (cg-RX-API-DMAC10.html)
SI (1) SI4225753T1 (cg-RX-API-DMAC10.html)
WO (1) WO2022074103A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102993831B1 (ko) 2020-10-08 2026-07-23 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조
CN117903116A (zh) * 2021-08-27 2024-04-19 杭州阿诺生物医药科技有限公司 细胞周期蛋白k降解剂
JP2026521568A (ja) 2023-06-16 2026-06-30 レウコス バイオテク ソシエダッド リミターダ 5-htr1b調節因子を用いた固形腫瘍の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW240217B (cg-RX-API-DMAC10.html) 1992-12-30 1995-02-11 Glaxo Group Ltd
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
SK492001A3 (en) 1998-07-20 2001-08-06 Merck Patent Gmbh Biphenyl derivatives
HUP0302966A2 (hu) 2000-07-31 2003-12-29 Smithkline Beecham P.L.C. Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
WO2007077457A2 (en) 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists
EP3348266A1 (en) 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer

Also Published As

Publication number Publication date
US20260138974A1 (en) 2026-05-21
US20240166639A1 (en) 2024-05-23
WO2022074103A1 (en) 2022-04-14
CL2023001021A1 (es) 2023-11-24
FI4225753T3 (fi) 2024-08-29
DK4225753T3 (da) 2024-08-19
CN116635390A (zh) 2023-08-22
CN116635390B (zh) 2026-03-27
ES2985416T3 (es) 2024-11-05
CA3194700A1 (en) 2022-04-14
JP7687636B2 (ja) 2025-06-03
LT4225753T (lt) 2024-08-26
IL301806B1 (en) 2026-01-01
US12540133B2 (en) 2026-02-03
EP4445901A3 (en) 2024-12-04
PT4225753T (pt) 2024-08-30
HRP20241184T1 (hr) 2024-11-22
EP4445901A2 (en) 2024-10-16
SI4225753T1 (sl) 2024-10-30
EP4225753A1 (en) 2023-08-16
IL301806A (en) 2023-05-01
AU2021356114A9 (en) 2024-09-12
IL301806B2 (en) 2026-05-01
PL4225753T3 (pl) 2024-11-18
EP4225753B1 (en) 2024-07-31
JP2023547346A (ja) 2023-11-10
HUE068199T2 (hu) 2024-12-28
AU2021356114A1 (en) 2023-05-18
RS65956B1 (sr) 2024-10-31
MX2023004116A (es) 2023-06-13

Similar Documents

Publication Publication Date Title
CN112552294B (zh) 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
CN113214287B (zh) Hpk1抑制剂及其使用方法
CN110573500B (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
JP2023536948A (ja) Egfr阻害剤およびその製造方法と応用
CA3002416C (en) Benzimidazolyl derivatives for use as ferroportin inhibitors
US20260138974A1 (en) Potent and selective compounds as serotonin 1b receptor modulators
CN118221698A (zh) Kras g12d抑制剂
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
CN111601790B (zh) 作为蛋白激酶抑制剂的杂芳基化合物
CN105968115B (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
KR20110016998A (ko) 키나제 억제제로서의 아자카르볼린 유도체, 그의 제조 및 그의 치료 용도
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
IL305046A (en) Pyridopyrimidinone derivative, the method of preparation thereof and its use
CN105712992A (zh) 作为cMet抑制剂的化合物及其制备方法和用途
JPWO2016098793A1 (ja) 環状グアニジル基を有するチアゾール誘導体
JP2024516194A (ja) Pd1/pd-l1阻害剤としての化合物及びその方法
CN107056754B (zh) 内嵌脲类结构的wnt通路抑制剂
HK40057478B (en) Hpk1 inhibitors and methods of using same
JP2025526321A (ja) Tead阻害薬および使用方法
JP2025539873A (ja) Hur(elavl1)を調節するための化合物
HK40047614A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HK40047614B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000